Abstract
The most comprehensive review to date of medicinal cannabinoids for the treatment of mental disorders has concluded that the evidence is insufficient to justify their use. A greater number of high‐quality trials is necessary to assess the safety and efficacy of medical cannabis and derivatives such as the increasingly popular cannabidiol (CBD), authors of the review and meta‐analysis stated. Results were published online Oct. 28 in Lancet Psychiatry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
